D6PV — a new drug to quickly lower triglycerides in acute pancreatitis
IND-enabling studies of D6PV- a novel ApoC-II peptide mimetic therapeutic
A new IV peptide called D6PV is being developed to quickly lower very high triglycerides in people with acute pancreatitis and will start with safety testing in healthy volunteers.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Protean Bio INC. NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-11182385 on NIH RePORTER |
What this research studies
Researchers are preparing D6PV, an ApoC-II peptide mimetic, as an intravenous medicine by completing toxicology studies and making the drug under GMP conditions to meet regulatory requirements. They will determine safe dosing limits in preclinical studies and use that information to support first‑in‑human Phase 1 trials in healthy adult volunteers with single and multiple ascending doses. If Phase 1 shows acceptable safety and pharmacokinetics, the drug is planned to move into hospital trials for adults with acute pancreatitis to see if a single IV dose can lower triglycerides within four hours. The overall goal is a fast-acting treatment to reduce complications, shorten hospital stays, and lower morbidity from hypertriglyceridemia-driven pancreatitis.
Who could benefit from this research
Good fit: Initially healthy adult volunteers will be recruited for Phase 1 safety studies, and later hospitalized adults with acute pancreatitis and markedly elevated triglycerides would be candidates for efficacy trials.
Not a fit: People without acute pancreatitis or without severely elevated triglycerides, as well as those excluded for medical or pregnancy reasons, are unlikely to benefit from this treatment.
Why it matters
Potential benefit: If successful, D6PV could rapidly lower triglycerides in hospitalized acute pancreatitis patients and potentially reduce complications, length of stay, and death.
How similar studies have performed: This mechanism is relatively novel: existing treatments lower triglycerides by other means, while ApoC-II peptide mimetics like D6PV are largely untested in humans and represent a new approach.
Where this research is happening
Lexington, United States
- Protean Bio INC. — Lexington, United States (Active)
Researchers
- Principal investigator: Devalaraja, Matt — Protean Bio INC.
- Study coordinator: Devalaraja, Matt
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.